

# MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



---

1

Diagnosis and management of type 1 diabetes in children, young people and adults |  
Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/cg15>

2

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.  
<https://www.nice.org.uk/guidance/ng28>

3

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes  
Systematic review and mixed-treatment comparison analysis.  
<http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

4

Obesity: identification, assessment and management | Guidance and guidelines | NICE.  
<https://www.nice.org.uk/guidance/cg189>

5

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International  
Federation on Ageing.  
<https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

6

NHS Evidence: an introduction.

[http://www.solent.nhs.uk/\\_store/documents/nhs\\_evidence\\_guide.pdf](http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf)

7

Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley &amp; Sons, Incorporated 2016.

<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

8

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.

<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

9

Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine 2012;**2**:a007641–a007641. doi:10.1101/cshperspect.a007641

10

Jelinek HF, Stranieri A, Yatsko A, et al. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine 2016;**75**:90–7. doi:10.1016/j.compbiomed.2016.05.005

11

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes 2015;**5**. doi:doi: 10.1038/nutd.2015.16

12

Samuel VT, Shulman GI. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell 2012;**148**:852–71. doi:10.1016/j.cell.2012.02.017

13

Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open* 2015;**5**. doi:doi:10.1136/bmjopen-2015-009088

14

Zaccardi F, Webb DR, Yates T, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal* 2016;**92**:63–9. doi:10.1136/postgradmedj-2015-133281

15

Anthony H. Barnett, Jenny Grice. *New Mechanisms in Glucose Control*. BMJ Books; 1 edition 2013. <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

16

Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care* Published Online First: 10 August 2017. doi:10.2337/dci16-0055

17

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

18

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010. <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

19

Copeland KC, Silverstein J, Moore KR, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS* 2013;**131**:364–82. doi:10.1542/peds.2012-3494

20

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine* 2010;**3**. doi:doi: 10.1258/om.2010.100025

21

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine* 2009;**2**. doi:doi: 10.1258/om.2009.080049

22

Schwartz SS, Epstein S, Corkey BE, et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the  $\beta$ -Cell-Centric Classification Schema. *Diabetes Care* 2016;**39**:179–86. doi:10.2337/dc15-1585

23

Nolan CJ, Ruderman NB, Kahn SE, et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes* 2015;**64**:673–86. doi:10.2337/db14-0694

24

Gale EA. Is type 2 diabetes a category error? *The Lancet* 2013;**381**:1956–7. doi:10.1016/S0140-6736(12)62207-7

25

Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports* 2016;**16**. doi:10.1007/s11892-016-0717-7

26

Noctor E, Dunne F. Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology* 2015;**3**:761–2. doi:10.1016/S2213-8587(15)00322-8

27

Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology* 2015;**3**:752–3. doi:10.1016/S2213-8587(15)00282-X

28

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine* 2015;**8**. doi:doi:10.1177/1753495X15590713

29

Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine* 2016;**375**:644–54. doi:10.1056/NEJMoa1602494

30

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). <https://www.nice.org.uk/guidance/ng3>

31

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine* 2013;**30**:803–17. doi:10.1111/dme.12159

32

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - *Diabetes & Primary Care*.  
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

33

Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John

Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD011970.pub2

34

Rasouli B, Andersson T, Carlsson P-O, et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine* 2017;**34**:1259–63. doi:10.1111/dme.13410

35

Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. *Diabetic Medicine* 2017;**34**:1340–53. doi:10.1111/dme.13400

36

Perrin NE, Davies MJ, Robertson N, et al. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine* 2017;**34**:1508–20. doi:10.1111/dme.13448

37

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

38

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

39

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care* 2015;**38**:S4–S4. doi:10.2337/dc15-S003

40

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.  
<http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

41

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE 2015; **10**. doi:doi: 10.1371/journal.pone.0135702

42

Tao L, Wilson ECF, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine 2015;**32**:907–19. doi:10.1111/dme.12711

43

Gray LJ, Khunti K, Wilmot EG, et al. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice 2014;**104**:451–8. doi:10.1016/j.diabres.2014.03.018

44

Gray LJ, Khunti K, Edwardson C, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia 2012;**55**:3238–44. doi:10.1007/s00125-012-2725-8

45

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;**38**:140–9. doi:10.2337/dc14-2441

46

Guidelines. <https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

47

Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

48

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

49

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

50

Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ* 2008;**336**:491–5. doi:10.1136/bmj.39474.922025.BE

51

Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA* 2014;**312**. doi:10.1001/jama.2014.10397

52

Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care* 2016;**39**:808–15. doi:10.2337/dc15-1942



53

Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine* 2015;**32**:1149–55.  
doi:10.1111/dme.12722

54

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE* 2013;**8**. doi:doi: 10.1371/journal.pone.0058861

55

Chimen M, Kennedy A, Nirantharakumar K, et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia* 2012;**55**:542–51.  
doi:10.1007/s00125-011-2403-2

56

Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA<sub>1c</sub> Levels in Type 2 Diabetes. *JAMA* 2011;**305**.  
doi:10.1001/jama.2011.576

57

Avery L, Flynn D, van Wersch A, et al. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care* 2012;**35**:2681–9. doi:10.2337/dc11-2452

58

Barry VW, Baruth M, Beets MW, et al. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases* 2014;**56**:382–90.  
doi:10.1016/j.pcad.2013.09.002

59

Qin L, Knol MJ, Corpeleijn E, et al. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology* 2010;**25**

:5-12. doi:10.1007/s10654-009-9395-y

60

Lee I-M. Physical Activity and Weight Gain Prevention. JAMA 2010;**303**.  
doi:10.1001/jama.2010.312

61

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity.  
The American Journal of Clinical Nutrition 2005;**82**  
:226S-229S.<http://ajcn.nutrition.org/content/82/1/226S>

62

Heinonen I, Helajärvi H, Pahkala K, et al. Sedentary behaviours and obesity in adults: the  
Cardiovascular Risk in Young Finns Study. BMJ Open 2013;**3**.  
doi:10.1136/bmjopen-2013-002901

63

Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic  
quadrennium. The Lancet 2016;**388**:1325-36. doi:10.1016/S0140-6736(16)30581-5

64

Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. New England  
Journal of Medicine 2016;**375**:1187-9. doi:10.1056/NEJMc1de1515935

65

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk  
Population. Published Online First: 10 November  
2014.<https://lra.le.ac.uk/handle/2381/32505>

66

The Eatwell Guide. Public Health England 2016.  
<https://www.gov.uk/government/publications/the-eatwell-guide>

67

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review)  
TA151, July 2008. <http://www.nice.org.uk/guidance/ta151>

68

Hadjiconstantinou M, Byrne J, Bodicoat DH, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research* 2016;**18**. doi:10.2196/jmir.5991

69

Young-Hyman D, de Groot M, Hill-Briggs F, et al. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;**39**:2126–2140. *Diabetes Care* 2017;**40**:287.1-287. doi:10.2337/dc17-er02

70

Capehorn M, Polonsky WH, Edelman S, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ). *Diabetic Medicine Published Online First*: March 2017. doi:10.1111/dme.13357

71

Hartman YAW, Jansen HJ, Hopman MTE, et al. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care* 2017;**40**:e120–1. doi:10.2337/dc17-0787

72

Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. *Diabetic Medicine* 2017;**34**:1228–34. doi:10.1111/dme.13381

73

Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. *Diabetic Medicine* 2017;**34**:1546–53. doi:10.1111/dme.13451

74

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. *Diabetes Care*  
[http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT\\_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GAL E%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true](http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GAL E%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true)

75

Constructs of depression and distress in diabetes: time for an appraisal- *ClinicalKey*.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

76

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

77

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

78

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a

randomised, double-blind, non-inferiority trial. *The Lancet* 2012;**380**:475–83.  
doi:10.1016/S0140-6736(12)60691-6

79

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology* 2016;**90**:1861–81. doi:10.1007/s00204-016-1737-4

80

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine* 2007;**356**:2457–71.  
doi:10.1056/NEJMoa072761

81

Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine* 2016;**165**.  
doi:10.7326/ACPJC-2016-165-4-020

82

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice* 2015;**109**:378–88. doi:10.1016/j.diabres.2015.05.025

83

Bennett WL, Maruthur NM, Singh S, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine* 2011;**154**.  
doi:10.7326/0003-4819-154-9-201105030-00336

84

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy* 2016;**7**. doi:doi:10.1007/s13300-016-0189-4

85

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy* 2014; **5**. doi:doi: 10.1007/s13300-014-0061-3

86

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

87

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

88

Ryder B, McKnight J, Blann A, et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes* 2013;**30**:388-91. doi:10.1002/pdi.1816

89

Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA* 2007;**298**. doi:10.1001/jama.298.2.194

90

Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet* 2009;**374**:39-47. doi:10.1016/S0140-6736(09)60659-0

91

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE.  
<http://www.nice.org.uk/guidance/PH38>

92

Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care* 2010;**33**:1255–61. doi:10.2337/dc09-1914

93

Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine* 2011;**154**. doi:10.7326/0003-4819-154-2-201101180-00300

94

Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet* 2010;**375**:2223–33. doi:10.1016/S0140-6736(10)60407-2

95

Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet* 2010;**375**:2234–43. doi:10.1016/S0140-6736(10)60406-0

96

Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism* 2007;**9**:194–205. doi:10.1111/j.1463-1326.2006.00704.x

97

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE.  
<https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

98

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* Published Online First: 15 September 2016. doi:10.1056/NEJMoa1607141

99

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology* 2016;**4**:525–36. doi:10.1016/S2213-8587(15)00482-9

100

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE.  
<https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

101

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013.  
<http://www.nice.org.uk/guidance/ta288>

102

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015.  
<https://www.nice.org.uk/guidance/ta248>

103

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.  
<https://www.nice.org.uk/guidance/ta203>

104

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:311–22.  
doi:10.1056/NEJMoa1603827



105

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:1797–9. doi:10.1056/NEJMc1611289

106

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:323–34. doi:10.1056/NEJMoa1515920

107

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:1799–802. doi:10.1056/NEJMc1611290

108

Courtney H, Nayar R, Rajeswaran C, et al. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2017;**Volume 10**:79–87. doi:10.2147/DMSO.S126763

109

Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 2015;**373**:232–42. doi:10.1056/NEJMoa1501352

110

Rotz ME, Ganetsky VS, Sen S, et al. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice* 2015;**69**:531–49. doi:10.1111/ijcp.12572

111

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes

in Type 2 Diabetes. *New England Journal of Medicine* 2016;**375**:311–22.  
doi:10.1056/NEJMoa1603827

112

Levin PA, Nguyen H, Wittbrodt E, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2017;**Volume 10**:123–39. doi:10.2147/DMSO.S130834

113

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

114

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

115

Leff DR, Heath D. Surgery for obesity in adulthood. *BMJ* 2009;**339**:b3402–b3402.  
doi:10.1136/bmj.b3402

116

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine* 2012;**366**:1567–76. doi:10.1056/NEJMoa1200225

117

Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care* 2013;**36**:2489–96.  
doi:10.2337/dc12-2454

118

Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine* 2004;**351**:2683–93. doi:10.1056/NEJMoa035622

119

Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine* 2016;**375**:1090–2. doi:10.1056/NEJMcibr1607950

120

Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine* 2016;**375**:1054–67. doi:10.1056/NEJMra1501993

121

National Obesity Observatory. <http://www.noo.org.uk>

122

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine* 2017;**376**:641–51. doi:10.1056/NEJMoa1600869

123

Min SH, Yoon J-H, Hahn S, et al. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews* 2017;**33**. doi:10.1002/dmrr.2818

124

Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised,

open-label, phase 3, non-inferiority trial. *The Lancet* 2014;**384**:1349–57.  
doi:10.1016/S0140-6736(14)60976-4

125

Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care* 2014;**37**:2149–58. doi:10.2337/dc13-2761

126

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine* 2017;**376**:641–51.  
doi:10.1056/NEJMoa1600869

127

Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care* 2017;**40**:494–501. doi:10.2337/dc16-1135

128

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

129

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.  
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

130

Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine* 2010;**363**:311–20. doi:10.1056/NEJMoa1002853

131

Choudhary P, Parrott NR, Birtles L, et al. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes* 2012;**29**:280–5. doi:10.1002/pdi.1707

132

Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine* 2012;**366**:1616–24. doi:10.1056/NEJMct1113948

133

Srinivasan P, Huang GC, Amiel SA, et al. Islet cell transplantation. *Postgraduate Medical Journal* 2007;**83**:224–9. doi:10.1136/pgmj.2006.053447

134

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.  
<https://www.nice.org.uk/guidance/ta203>

135

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine* 2017;**34**:1205–11. doi:10.1111/dme.13379

136

Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine* 2017;**34**:1361–6. doi:10.1111/dme.13427

137

Leelarathna L, Roberts SA, Hindle A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine* 2017;**34**:1372–9. doi:10.1111/dme.13412

138

Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine* 2017;**34**:1498–9. doi:10.1111/dme.13445

139

Narendran P, Jackson N, Daley A, et al. Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine* 2017;**34**:1521–31. doi:10.1111/dme.13439

140

Holt RIG, Cockram C, Flyvbjerg A, et al. *Textbook of Diabetes*. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.

<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

141

Holt RIG. *Textbook of diabetes*. 4th ed. Chichester: : Wiley-Blackwell 2010.

<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

142

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology (Online)*;**3**.<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

143

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care* 2015;**38**:1583–91. doi:10.2337/dc15-0279

144

[ARCHIVED CONTENT] *Medicines management: Everybody's business* : Department of Health - Publications and statistics.

[http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh\\_082200](http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200)

145

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. <https://www.nice.org.uk/guidance/cg76>

146

Grammes J, Stock W, Mann CG, et al. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine* Published Online First: 30 August 2017. doi:10.1111/dme.13506

147

Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine* 2017;**34**:1456–60. doi:10.1111/dme.13438

148

Vloemans AF, van Beers CAJ, de Wit M, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine* 2017;**34**:1470–6. doi:10.1111/dme.13429

149

Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice* 2008;**82**:S118–21. doi:10.1016/j.diabres.2008.09.051

150

Bailey, Stephen. *Academic Writing : A Handbook for International Students*. <http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

151

Creame P, Lea MR. *Writing At University: A Guide For Students*. 3rd ed. Maidenhead: :

McGraw-Hill Education 2008.

<https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>